OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OMEICOS Therapeutics GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10960
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OMEICOS Therapeutics GmbH (OMEICOS) is a biopharmaceutical company that develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. The company utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to develop therapeutics. Its clinical product candidate includes OMT-28, a synthetic small molecule analog of the omega-3 fatty acid metabolite 17, 18-EEQ which is developed for the treatment of paroxysmal and persistent atrial fibrillation, ventricular arrhythmia, myocardial infarction, macular edema diseases, and kidney injury. The company also conducts research and development activities. OMEICOS is headquartered in Berlin, Germany.

OMEICOS Therapeutics GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OMEICOS Therapeutics Raises USD19.34 Million in Series C Financing 11
OMEICOS Therapeutics Raises Additional Funds through Series B Financing 13
Omeicos Therapeutics Raises USD8.8 Million in Series B Financing 14
Omeicos Therapeutics Raises USD6.6 Million in Series A Venture Financing 16
Omeicos Therapeutics Secures Venture Funding 18
OMEICOS Therapeutics GmbH – Key Competitors 19
OMEICOS Therapeutics GmbH – Key Employees 20
OMEICOS Therapeutics GmbH – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Corporate Communications 22
Apr 27, 2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics 22
Product News 23
06/07/2017: OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases 23
04/27/2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics 24
Clinical Trials 25
Jul 17, 2018: OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation 25
Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board 26
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Key Facts 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OMEICOS Therapeutics GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OMEICOS Therapeutics Raises USD19.34 Million in Series C Financing 11
OMEICOS Therapeutics Raises Additional Funds through Series B Financing 13
Omeicos Therapeutics Raises USD8.8 Million in Series B Financing 14
Omeicos Therapeutics Raises USD6.6 Million in Series A Venture Financing 16
Omeicos Therapeutics Secures Venture Funding 18
OMEICOS Therapeutics GmbH, Key Competitors 19
OMEICOS Therapeutics GmbH, Key Employees 20
OMEICOS Therapeutics GmbH, Subsidiaries 21

List of Figures
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OMEICOS Therapeutics GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Globeleq Africa Ltd:企業の戦略的SWOT分析
    Globeleq Africa Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • The Greenbrier Companies, Inc.:企業の戦略・SWOT・財務分析
    The Greenbrier Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Greenbrier Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Caixa Geral de Depositos SA:企業の戦略的SWOT分析
    Caixa Geral de Depositos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Instrumentation Laboratory Company-医療機器分野:企業M&A・提携分析
    Summary Instrumentation Laboratory Company (IL), a subsidiary of Werfen Life Group, is a medical device company with focus on in vitro diagnostics (IVD) devices. The company develops, manufactures, and distributes IVD instruments, related reagents and controls for hospitals and clinical laboratories …
  • Anglo American Plc:企業のM&A・事業提携・投資動向
    Anglo American Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anglo American Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Tampa Electric Co:発電所・企業SWOT分析
    Tampa Electric Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • SOM Biotech SL:製薬・医療:M&Aディール及び事業提携情報
    Summary SOM Biotech SL (SOM Biotech) is a drug repurposing company that discovers and develops new drugs for orphan indications. The company’s pipeline products include SOM0777, SOM0226, SOM3355, SOM1201 and SOM2201 are used for the treatment of TTR amyloidosis, glioblastoma, huntington disease, duc …
  • BioMarin Pharmaceutical Inc (BMRN):医療機器:M&Aディール及び事業提携情報
    Summary BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Kyndrisa (drisapersen), Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasi …
  • DiaGenic ASA (NEL)-医療機器分野:企業M&A・提携分析
    Summary DiaGenic ASA (DiaGenic) is a medical device company that develops innovative in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from th …
  • Printpack Inc:企業の戦略的SWOT分析
    Printpack Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Power Corporation of Canada:企業の戦略・SWOT・財務情報
    Power Corporation of Canada - Strategy, SWOT and Corporate Finance Report Summary Power Corporation of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • FedEx Corp:企業の戦略・SWOT・財務分析
    FedEx Corp - Strategy, SWOT and Corporate Finance Report Summary FedEx Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Laboratoire Aguettant SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratoire Aguettant (Aguettant) is a pharmaceutical company that offers development, manufacturing and commercialisation of essential hospital medicines. The company offers products under various categories such as specialist sectors and delivery systems. Its speciality sector offers emerg …
  • Jindal Hotels Ltd:企業の戦略・SWOT・財務情報
    Jindal Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Jindal Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Westar Energy Inc (WR):電力:M&Aディール及び事業提携情報
    Summary Westar Energy, Inc. (Westar Energy) is a vertically integrated energy utility that generates, transmits and distributes electricity. The company owns and operates a generation portfolio of coal-fired, nuclear, natural gas-based, renewable and diesel-based power plants. It also procures elect …
  • GW Pharmaceuticals Plc (GWPH):企業の財務・戦略的SWOT分析
    GW Pharmaceuticals Plc (GWPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • China Vanke Co., Ltd.:企業の戦略・SWOT・財務情報
    China Vanke Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary China Vanke Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • United Therapeutics Corp (UTHR):企業の製品パイプライン分析
    Summary United Therapeutics Corp (United Therapeutics) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues includin …
  • Clinical Innovations LLC-医療機器分野:企業M&A・提携分析
    Summary Clinical Innovations LLC (Clinical Innovations), a subsidiary of Pritzker Group Company is a medical device company that offers healthcare products for women and infants. The company offers products such as safety heelsticks, traxi panniculus retractor, ROM plus membrane testing, tamponade s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆